CD8A and neoplasm: The regulatory effects of anti-angiogenic drugs targeting VEGFA/VEGFR2 in immune cells, including CD8+T cells, Tregs, MDSCs, DCs, tumor-associated macrophages and mast cells [28] were worth of further study.